Nov 15 (Reuters) - EMA:
* EMA - CHMP RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR ISTURISA (OSILODROSTAT) FOR THE TREATMENT OF CUSHING’S SYNDROME
* EMA - TAVLESSE (FOSTAMATINIB) RECEIVED A POSITIVE OPINION FROM CHMP FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA
* EMA - CHMP ADOPTED A POSITIVE OPINION FOR SUNOSI FOR TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY & OBSTRUCTIVE SLEEP APNOEA
* EMA - CHMP RECOMMENDS RESTRICTING USE OF MULTIPLE SCLEROSIS MEDICINE LEMTRADA (ALEMTUZUMAB) DUE TO REPORTS OF RARE BUT SERIOUS SIDE EFFECTS
* EMA - CHMP RECOMMENDS CONDITIONAL MARKETING AUTHORISATION FOR POLIVY (POLATUZUMAB VEDOTIN) TO TREAT RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
* EMA - MAYZENT GOT POSITIVE OPINION FROM CHMP FOR TREATMENT OF ADULT PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS WITH ACTIVE DISEASE Source (bit.ly/33Q89N3) Further company coverage:
